Synaptics Incorporated (NASDAQ:SYNA) was more active in the last trading session as around 2.47 million shares exchanged hands on Wall Street, representing an increase from its normal capacity of 0.99 million shares. A 5.96% change after the initial price of $34.94, sent the closing price to $36.6.Synaptics Incorporated (SYNA) Analyst Opinion
Synaptics Incorporated has a consensus hold rating from 15 Wall Street analysts, and the number of shares currently sold short amount to at least 26.72% of shares outstanding. The stock sank -4.91% last month and is down -31.69 this year. Wall Street is only getting more bullish on the stock, with 8 of analysts who cover SYNA having a buy-equivalent rating. Analysts have placed a $52.77 price target on Synaptics Incorporated, suggesting a 44.18% gain from recent close. It’s currently trading about -43.29% below its 52-week high.
Synaptics Incorporated (SYNA) surprised the stock market in its last reported earnings when it earned $1.18 a piece versus the consensus-estimated $1.16. Its revenue totaled $426.49 million down -3.99% from the previous quarter.Synaptics Incorporated (NASDAQ:SYNA) Intraday View
This stock (SYNA) is ahead of its 52-week low with 8.51%. Its last month’s stock price volatility remained 4.4% which for the week stands at 3.58%. The share price has moved backward from its 20 days moving average, trading at a distance of -0.17% and stays -4.79% away from its 50 days moving average. Over the last five days, shares have faced -0.38% losses and now is down -25.52% since hitting its 200-day moving average of $47.49. Synaptics Incorporated (SYNA) has made its way to a 12-month decline of -31.13%.
Turning to Viking Therapeutics, Inc. (NASDAQ:VKTX), its shares were trading at $2.51 a gain of $0.12, on the trading floor. The stock, after opening at $2.4, touched a high of $2.55 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Viking Therapeutics, Inc. has 0 buy ratings, 0 holds and 0 sells even after the stock tumbled -22.53% from its high of $3.24 to a $72.46 million market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 2 to 2 during a month. Analysts set a 12-month price target of $7.33 a share. The target implies a 192.03% spike from where the shares are currently trading. Also, the current price highlights a discount of 298.41% to analysts’ high consensus price target.Viking Therapeutics, Inc. (NASDAQ:VKTX) Intraday Trading
The counter witnessed a trading volume of 0.38 million shares versus an average volume of 0.56 million shares during last trading session. Its last month’s stock price volatility remained 7.96% which for the week approaches 12.82%. The lowest price the stock reached in the last trading day was $2.36 and compares with the $0.88 52-week low. The stock recovered 185.23% since its low point and has performed 110.92% year-to-date.